Skip to main content
Cancer Cell International logoLink to Cancer Cell International
. 2020 Oct 2;20:479. doi: 10.1186/s12935-020-01575-3

Correction to: Downexpression of HSD17B6 correlates with clinical prognosis and tumor immune infiltrates in hepatocellular carcinoma

Lei Lv 1,#, Yujia Zhao 2,#, Qinqin Wei 2, Ye Zhao 2, Qiyi Yi 2,
PMCID: PMC7532554  PMID: 33024417

Correction to Cancer Cell Int (2020) 20:210 http://doi.org/10.1186/s12935-020-01298-5

Following publication of the original article [1], we were notified of a few changes in the author affiliations. The correct affiliations for the authors are listed below:

Lei Lv1,†, Yujia Zhao2,†, Qinqin Wei2, Ye Zhao2, Qiyi Yi2,*

1Anhui Provincial Cancer Hospital, West Branch of the First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei 230031, Anhui, People’s Republic of China.

2Teaching and Research Section of Nuclear Medicine, Anhui Medical University, 81 Meishan Road, Hefei 230032, Anhui, People’s Republic of China.

Footnotes

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Lei Lv and Yujia Zhao contributed equally to this work

Reference

  • 1.Lv L, Zhao Y, Wei Q, Zhao Y, Yi Q. Downexpression of HSD17B6 correlates with clinical prognosis and tumor immune infiltrates in hepatocellular carcinoma. Cancer Cell Int. 2020;20:210. doi: 10.1186/s12935-020-01298-5. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Cancer Cell International are provided here courtesy of BMC

RESOURCES